TBPH

8.93

3.25% -0.30

Handel nachbörslich: 8.93

Theravance Biopharma Inc (TBPH)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$9.23

Offen:

$9.11

24-Stunden-Volumen:

376.30K

Relative Volume:

1.78

Marktkapitalisierung:

$444.69M

Einnahmen:

$62.02M

Nettoeinkommen (Verlust:

$-45.65M

KGV:

-9.7065

EPS:

-0.92

Netto-Cashflow:

$-9.60M

1W Leistung:

-4.90%

1M Leistung:

-4.49%

6M Leistung:

+10.79%

1J Leistung:

-0.45%

1-Tages-Spanne:

$8.93

$9.15

1-Wochen-Bereich:

$8.93

$9.44

52-Wochen-Spanne:

$7.44

$10.90

Theravance Biopharma Inc Stock (TBPH) Company Profile

Firmenname

Theravance Biopharma Inc

Sektor

Healthcare (1164)

Branche

Biotechnology (681)

Telefon

650-808-6000

Adresse

UGLAND HOUSE, SOUTH CHURCH STREET, GEORGE TOWN, GRAND CAYMAN

Mitarbeiter

Twitter

Nächster Verdiensttermin

2024-11-12

Neueste SEC-Einreichungen

TBPH's Discussions on Twitter

Vergleichen Sie TBPH mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
TBPH Theravance Biopharma Inc	8.93	444.69M	62.02M	-45.65M	-9.60M	-0.92
VRTX Vertex Pharmaceuticals Inc	484.82	131.41B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	634.23	72.26B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	591.87	36.10B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	270.02	35.03B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	272.17	28.24B	3.81B	-644.79M	-669.77M	-6.24

Theravance Biopharma Inc Stock (TBPH) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-08-06	Herabstufung	Leerink Partners	Outperform → Market Perform
2024-04-12	Eingeleitet	BTIG Research	Buy
2024-01-08	Herabstufung	Evercore ISI	Outperform → In-line
2022-05-23	Eingeleitet	SVB Leerink	Outperform
2021-11-05	Hochstufung	JP Morgan	Underweight → Neutral
2021-09-15	Herabstufung	JP Morgan	Overweight → Underweight
2021-08-25	Herabstufung	Morgan Stanley	Overweight → Underweight
2021-08-24	Herabstufung	Cowen	Outperform → Market Perform
2020-10-14	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2020-07-07	Eingeleitet	JP Morgan	Overweight
2020-06-15	Eingeleitet	Morgan Stanley	Equal-Weight
2020-05-13	Eingeleitet	Cowen	Outperform
2020-01-08	Bestätigt	H.C. Wainwright	Buy
2019-11-06	Hochstufung	Robert W. Baird	Underperform → Neutral
2019-10-29	Eingeleitet	H.C. Wainwright	Buy
2018-03-29	Fortgesetzt	Piper Jaffray	Overweight
2017-08-17	Eingeleitet	Evercore ISI	Outperform
2017-06-16	Eingeleitet	Cantor Fitzgerald	Overweight
2017-05-11	Bestätigt	Needham	Buy
2016-12-21	Eingeleitet	Needham	Buy
2016-11-03	Eingeleitet	Piper Jaffray	Overweight
2016-10-12	Herabstufung	Robert W. Baird	Neutral → Underperform
2016-08-03	Herabstufung	BofA/Merrill	Neutral → Underperform
2016-06-20	Eingeleitet	Guggenheim	Buy
2016-06-20	Bestätigt	Leerink Partners	Outperform
2016-05-12	Eingeleitet	Leerink Partners	Outperform
2016-05-05	Herabstufung	BofA/Merrill	Buy → Neutral
2015-02-03	Hochstufung	Robert W. Baird	Underperform → Neutral

Alle ansehen

Theravance Biopharma Inc Aktie (TBPH) Neueste Nachrichten

06:00 AM

Exclusive Access: Theravance Biopharma Leadership Reveals Strategy at Jones Healthcare Conference - Stock Titan

06:00 AM

Mar 28, 2025

Why Is Theravance Bio (TBPH) Up 0.4% Since Last Earnings Report? - Yahoo Finance

Mar 28, 2025

Charles Schwab Investment Management Inc. Has $2.77 Million Stake in Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World

Mar 28, 2025

Mar 27, 2025

Theravance Biopharma to Present New Ampreloxetine Analyses in Neurogenic Orthostatic Hypotension (nOH) at the 77th Annual Meeting of the American Academy of Neurology - PR Newswire

Mar 27, 2025

Mar 25, 2025

Bank of New York Mellon Corp Sells 5,282 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World

Mar 25, 2025

Theravance Biopharma, Inc. (NASDAQ:TBPH) Receives $13.75 Consensus Price Target from Brokerages - Defense World

Mar 25, 2025

Mar 24, 2025

Q1 EPS Forecast for Theravance Biopharma Reduced by Analyst - Defense World

Mar 24, 2025

Mar 23, 2025

(TBPH) Investment Analysis - news.stocktradersdaily.com

Mar 23, 2025

Mar 18, 2025

Theravance Biopharma (NASDAQ:TBPH) Stock Crosses Above 50-Day Moving Average – What’s Next? - Defense World

Mar 18, 2025

Mar 10, 2025

Theravance Biopharma: Clinical Progress Is Not Enough To Make It Attractive - Seeking Alpha

Mar 10, 2025

Mar 08, 2025

Rhumbline Advisers Sells 3,110 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World

Mar 08, 2025

Mar 07, 2025

Theravance Biopharma (NASDAQ:TBPH) Share Price Passes Above 50-Day Moving AverageWhat's Next? - MarketBeat

Feb 28, 2025

Analysts Set Theravance Biopharma, Inc. (NASDAQ:TBPH) PT at $13.75 - MarketBeat

Feb 28, 2025

HC Wainwright Reiterates Buy Rating for Theravance Biopharma (NASDAQ:TBPH) - MarketBeat

Feb 28, 2025

Theravance Biopharma Reports Strong Q4 2024 Earnings - TipRanks

Feb 28, 2025

Investor Network: Theravance Biopharma Inc to Host Earnings Call - ACCESS Newswire

Feb 28, 2025

Research Analysts Issue Forecasts for TBPH FY2024 Earnings - Defense World

Feb 28, 2025

Feb 27, 2025

Theravance Biopharma (NASDAQ:TBPH) Releases Earnings Results, Misses Estimates By $0.26 EPS - MarketBeat

Feb 27, 2025

Theravance's Q4 Loss In Line With Estimates, Sales Beat - Yahoo Finance Australia

Feb 27, 2025

Theravance Biopharma, Inc. (NASDAQ:TBPH) Q4 2024 Earnings Call Transcript - Insider Monkey

Feb 27, 2025

FY2024 Earnings Forecast for TBPH Issued By HC Wainwright - MarketBeat

Feb 27, 2025

HC Wainwright Reiterates “Buy” Rating for Theravance Biopharma (NASDAQ:TBPH) - Defense World

Feb 27, 2025